NexMed has filed for approval in the US of its transdermal patch which delivers alprostadil to solve erectile dysfunction. Alprostadil already exists in the UK as a urethra suppository (MUSE) and an injection (Caverject.) If no further information is requested then approval could come in 8 months.
No data was available for the success rate of this delivery mechanism but it may be suitable for cases that cannot be treated with first line solutions such as Viagra. The inconvenient delivery mechanism for current alprostadil prescriptions has meant that the treatment is not popular with most men.
We will bring more news as and when we have it.